Blinatumomab SC2
20220107
Phase 2 small_molecule active
Quick answer
Blinatumomab SC2 for Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+) B-Cell Precursor Acute Lymphoblastic Leukemia is a Phase 2 program (small_molecule) at Amgen Technology (Ireland) UC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Amgen Technology (Ireland) UC
- Indication
- Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+) B-Cell Precursor Acute Lymphoblastic Leukemia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active